Home > Urology > EAU 2019 > Prostate Cancer > When to use imaging and imaging-guided therapies

When to use imaging and imaging-guided therapies

Presented By
Dr Lorenzo Bianchi, Dr Carlo Andrea Bravi
Conference
EAU 2019
A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT. Which patient with biochemical recurrence after primary treatment for prostate cancer would result in a positive 68 Ga-PSMA PET/CT? The 2019 EAU Guideline panel recommends performing 68 Ga-PSMA PET/CT if the PSA level is >0.2 ng/mL, providing the results will influence treatment decisions, but it is unclear if this is cost-effective. Dr Lorenzo Bianchi (University of Bologna, Italy) built a prediction model to assess the risk of individual patients to have a positive PET/CT. Prostate cancer patients (n=703) with confirmed biochemical recurrence were stratified according to different clinical settings of recurrence: first PSA relapse (detection rate 40%), biochemical relapse after salvage therapy (detection rate 54%), PSA persistence after primary therapy (detection rate 60%), and disease progression before starting systemic therapies (detection rate ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on